A PHASE 2, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE SAFETY AND EFFICACY OF NIRAPARIB IN PATIENTS WITH ADVANCED, RELAPSED, HIGH-GRADE SEROUS EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER WHO HAVE RECEIVED THREE OR FOUR PREVIOUS CHEMOTHERAPY REGIMENS

Registry ID

PR-30-5020-C

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

TESARO INC

Start date

2016-09-02

Last update

2016-03-02

Conditions

• OVARIAN CANCER
• FALLOPIAN TUBE CANCER
• OVARIAN CANCER PRIMARY PERITONEAL

Related clinical trials

• A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY OF SACITUZUMAB TIRUMOTECAN (SAC-TMT, MK-2870) MAINTENANCE TREATMENT WITH OR WITHOUT BEVACIZUMAB VERSUS STANDARD OF CARE IN PARTICIPANTS WITH NEWLY DIAGNOSE ADVANCED HRD-NEGATIVE OVARIAN CANCER FOLLOWING FIRST-LINE PLATINUMBASED CHEMOTHERAPY (TROFUSE-021/ENGOTOV85/GOG-3102)
• A PHASE 1B/2 OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RALUDOTATUG DERUXTECAN WITH OR WITHOUT OTHER ANTICANCER INVESTIGATIONAL AGENTS IN PARTICIPANTS WITH HIGH-GRADE SEROUS EPITHELIAL OVARIAN, PRIMARY PERITONEAL, OR FALLOPIAN TUBE CANCER WHO HAVE RELAPSED AFTER PRIOR PLATINUM-BASED CHEMOTHERAPY
• A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY TO INVESTIGATE GSK5733584 COMPARED WITH CHEMOTHERAPY IN PARTICIPANTS WITH PLATINUM-RESISTANT OVARIAN CANCER
• A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SACITUZUMAB TIRUMOTECAN (MK-2870) MAINTENANCE TREATMENT WITH OR WITHOUT BEVACIZUMAB VERSUS STANDARD OF CARE AFTER SECOND-LINE PLATINUM-BASED DOUBLET CHEMOTHERAPY IN PARTICIPANTS WITH PLATINUM-SENSITIVE RECURRENT OVARIAN CANCER (TROFUSE-022/ENGOT-OV84/GOG-3103)
• CATALINA-2: A PHASE 2 STUDY EVALUATING THE EFFICACY AND SAFETY OF TORL-1-23 IN WOMEN WITH ADVANCED PLATINUM-RESISTANT EPITHELIAL OVARIAN CANCER (INCLUDING PRIMARY PERITONEAL AND FALLOPIAN TUBE CANCERS) EXPRESSING CLAUDIN 6 (CLDN6)
• A RANDOMIZED PHASE 2 STUDY OF OCULAR TOXICITY EVALUATION AND MITIGATION DURING TREATMENT WITH MIRVETUXIMAB SORAVTANSINE IN PATIENTS WITH RECURRENT OVARIAN CANCER WITH HIGH FOLATE RECEPTOR-ALPHA EXPRESSION

View on source registry